Clinical Trial Update: A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NST-6179 for intestinal failure-associated liver disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intestinal Failure-associated Liver Disease

Drugs mentioned

• NST-6179 (NST-6179)

Snippet

Sponsor: NorthSea Therapeutics B.V. | Conditions: Intestinal Failure Associated Liver Disease | Phase 2 | Status: RECRUITING